Health startup ZappRx began with a goal to be patients' electronic link to the pharmacy. Now, the firm has raised an additional $1 million in seed funding to streamline the prescription process, according to VentureBeat.

ZappRx wants to focus initially on patients suffering from pulmonary arterial hypertension (PAH). This is a condition that affects around 2% of the specialty market, the report explained.

The latest funding round brings ZappRx's total raised capital to $2.2 million. Atlast Ventures led the financing. SR One (GlaxoSmithKline's venture arm), Terry Meguid, Sean Trigony, physicist James Glimm, and David Hamamoto also participated in the said round, the report detailed.

Founder and chief executive Zoe Barry said: "Specialty pharmacies cater to a lower volume of patients but they are often high need patients living with chronic and complex conditions. The drugs to treat these conditions are also complex and as a result high margin. We realized in consulting with our advisors that this was a far better space to start in given the current lack of options that exist for processing these types of orders."